• 1. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 2. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 3. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 4. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 5. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119

Recent Advances in the Study of Cyclopentanecarboxylic acid, 1-(4-iodophenyl)- (CAS: 135569-28-7)

Cyclopentanecarboxylic acid, 1-(4-iodophenyl)- (CAS: 135569-28-7) is a specialized chemical compound that has garnered significant attention in the field of chemical biology and pharmaceutical research. This compound, characterized by its cyclopentane backbone and iodophenyl substituent, has shown potential in various therapeutic applications, including as a building block for more complex pharmacophores. Recent studies have explored its synthesis, biological activity, and potential applications in drug discovery, making it a compound of interest for researchers in medicinal chemistry.

One of the key areas of research involving Cyclopentanecarboxylic acid, 1-(4-iodophenyl)- is its role in the development of novel anti-inflammatory and anticancer agents. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibit potent inhibitory effects on specific inflammatory pathways, particularly those involving cyclooxygenase-2 (COX-2). The study highlighted the compound's ability to modulate inflammatory responses with minimal side effects, suggesting its potential as a lead compound for developing new anti-inflammatory drugs.

In addition to its anti-inflammatory properties, recent research has also investigated the anticancer potential of Cyclopentanecarboxylic acid, 1-(4-iodophenyl)-. A study conducted by researchers at the University of Cambridge and published in Bioorganic & Medicinal Chemistry Letters in early 2024 revealed that this compound can induce apoptosis in certain cancer cell lines, particularly those associated with breast and prostate cancers. The mechanism of action appears to involve the disruption of mitochondrial function and the activation of caspase pathways, which are critical for programmed cell death. These findings open new avenues for the development of targeted cancer therapies.

The synthesis and optimization of Cyclopentanecarboxylic acid, 1-(4-iodophenyl)- have also been a focus of recent research. A 2023 paper in Organic Letters detailed a novel, high-yield synthetic route for this compound, utilizing palladium-catalyzed cross-coupling reactions. This method not only improves the efficiency of production but also allows for the introduction of various functional groups, enabling the creation of a diverse library of derivatives for further biological testing. Such advancements in synthetic methodology are crucial for accelerating drug discovery efforts.

Despite these promising developments, challenges remain in the clinical translation of Cyclopentanecarboxylic acid, 1-(4-iodophenyl)- and its derivatives. Issues such as bioavailability, metabolic stability, and potential toxicity need to be addressed through further preclinical studies. However, the compound's unique structural features and demonstrated biological activities make it a valuable candidate for continued investigation. Future research directions may include the exploration of its interactions with other molecular targets, as well as the development of more potent and selective analogs.

In conclusion, Cyclopentanecarboxylic acid, 1-(4-iodophenyl)- (CAS: 135569-28-7) represents a promising scaffold in medicinal chemistry, with demonstrated potential in anti-inflammatory and anticancer applications. Recent studies have shed light on its mechanisms of action, synthetic accessibility, and therapeutic possibilities. As research progresses, this compound may serve as a foundation for the development of next-generation pharmaceuticals, addressing unmet medical needs in inflammation and oncology.

• 124276-89-7(1-(4-Iodophenyl)cyclopropane-1-carboxylic Acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)